ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Financial Statements and Exhibits

ME Staff 8-k
-
0

ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Financial Statements and Exhibits
Item 9.01(d)of the Amended 8-K to update and replace the Consent of KPMG LLP included in Exhibit23.1 to the Amended 8-K. Other than as set forth in this Explanatory Note, this Form8-K/A does not amend any other items in the Amended 8-K or include any other modifications to the exhibits included as part of the Amended 8-K.

Item 9.01. Financial Statements and Exhibits

(d)Exhibits

EXHIBIT NO.

DESCRIPTION

23.1

Consent of KPMG LLP

EXHIBITINDEX

EXHIBIT NO.

DESCRIPTION

23.1

Consent of KPMG LLP


Aralez Pharmaceuticals Inc. Exhibit
EX-23.1 2 a17-26343_1ex23d1.htm EX-23.1 Exhibit 23.1   Consent of Independent Auditors   We consent to the incorporation by reference in the registration statements (Nos. 333-208822,…
To view the full exhibit click here

About ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).